Meeting
2015 ASCO Annual Meeting
HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).
Authors
Frankie Ann Holmes
Texas Oncology, US Oncology, Houston, TX
Frankie Ann Holmes , Corinne Ramos , Nicholas N Hoke , Maren K. Levin , Virginia A. Espina , Lance A. Liotta , Kai Wang , Norma Alonzo Palma , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 621)
DOI
10.1200/jco.2015.33.15_suppl.621
Abstract #
621
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.
First Author: Frankie Ann Holmes
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey
Poster
2014 ASCO Annual Meeting
Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy.
First Author: Phil Stephens
Poster
2013 ASCO Annual Meeting
Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.
First Author: Jeffrey S. Ross